Literature DB >> 19180340

Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil.

Denise Eri Onodera Vieira1, Mauro Gomes.   

Abstract

OBJECTIVES: To determine the frequency of adverse effects related to the use of the tuberculosis treatment regimen designated Regimen I and the need for regimen alterations due to these effects.
METHODS: A retrospective analysis of 329 medical charts of patients who were treated with Regimen I and discharged after cure between March 2000 and April 2006 was carried out at the Tuberculosis Outpatient Clinic, Department of Pulmonology of the Santa Casa de Misericórdia de São Paulo Hospital in the city of São Paulo, Brazil. Adverse effects and the timing of their appearance, as well as subsequent modifications in the treatment regimen, were investigated.
RESULTS: We included 297 patients, 146 (49.1%) of whom presented one or more adverse effects related to antituberculosis medications. The frequency of minor side effects was 41.1%, and that of major side effects was 12.8%. The most common reactions were those involving the gastrointestinal tract (40.3%) and the skin (22.1%). Adverse effects were more common in the first and second months of treatment (58.4%). Modification of the treatment regimen was necessary in 11 cases (3.7% of the total sample). Drug-induced hepatitis was the adverse effect that demanded the most regimen changes.
CONCLUSIONS: In this group of patients, the frequency of adverse effects related to treatment with Regimen I was 49.1%. However, in most of the cases, it was not necessary to modify the treatment regimen due to side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19180340     DOI: 10.1590/s1806-37132008001200010

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  9 in total

1.  Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.

Authors:  Mariam El Hamdouni; Samir Ahid; Jamal Eddine Bourkadi; Jouda Benamor; Mohammed Hassar; Yahia Cherrah
Journal:  Infection       Date:  2019-06-04       Impact factor: 7.455

Review 2.  Risk factors associated with adverse reactions to antituberculosis drugs.

Authors:  Laíse Soares Oliveira Resende; Edson Theodoro Dos Santos-Neto
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

3.  HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.

Authors:  Neesha Rockwood; Graeme Meintjes; Maxwell Chirehwa; Lubbe Wiesner; Helen McIlleron; Robert J Wilkinson; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Pharmaceutical interventions in the management of tuberculosis in a pneumophtisiology department, Ivory Coast.

Authors:  Danho Pascal Abrogoua; Boua Alexis Thierry Kamenan; Brou Jean Marcel Ahui; Elisée Doffou
Journal:  Ther Clin Risk Manag       Date:  2016-11-22       Impact factor: 2.423

5.  Evaluation of Adverse Reactions Induced by Anti-Tuberculosis Drugs in Hospital Pulau Pinang.

Authors:  Cheah Meng Fei; Hadzliana Zainal; Irfhan Ali Hyder Ali
Journal:  Malays J Med Sci       Date:  2018-10-30

6.  Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study.

Authors:  María B Arriaga; Ninfa M C Torres; Nelia C N Araujo; Simone C C Caldas; Bruno B Andrade; Eduardo M Netto
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

7.  Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

Authors:  Yin Yin Xia; Dai Yu Hu; Fei Ying Liu; Xiao Meng Wang; Yan Li Yuan; De Hua Tu; Yi Xin Chen; Lin Zhou; Li Zhen Zhu; Wei Wei Gao; Hong Yuan Wang; Da Fang Chen; Li Yang; Ping Ping He; Xiao Ting Li; Ying Jian He; Feng Sun; Si Yan Zhan
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

8.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

9.  Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST.

Authors:  Eliana Abreu Santos; José Carlos Saraiva Gonçalves; Marcos K Fleury; Afrânio L Kritski; Martha M Oliveira; Luciane S Velasque; José Roberto Lapa E Silva; Rita de Cássia E Estrela
Journal:  Braz J Infect Dis       Date:  2019-11-04       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.